Form 4 for STRO SUTRO BIOPHARMA, INC.
Accepted 2023-08-29 00:00:00 ET · period of report 2023-08-28 · accession 0001209191-23-047608 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-29 | 2023-08-28 | STRO | Shtylla Brunilda | Chief Business Off | S - Sale | $4.71 | -15.4K | 0 | -100% | -$72.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-28 | S | D | 15,428 | $4.71 | 0 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.745, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F2) The total number of shares of the Issuer's Common Stock owned before giving effect to the reported sale included 2,500 shares previously acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions that are exempt pursuant to Rules 16b-3(c) and 16b-3(d). |